

August 26, 2021

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub: Outcome of the Board Meeting held on August 26, 2021

We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Audited Financial Results for Financial Year ended June 30, 2021 were approved.

We are enclosing herewith the following:

- a. Audited Financial Results for the Financial Year ended June 30, 2021, as per format prescribed under Regulation 33 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015;
- b. Auditor's Report, in respect of the aforementioned Financial Results, as furnished by the Statutory Auditors of the Company;
- c. Press Release; and
- d. A declaration with respect to Audit Report with unmodified opinion to the aforementioned Audited Financial Results

We are pleased to further inform you that the Board of Directors of the Company at its meeting held today, *inter alia*, have recommended a final dividend of Rs. 130 per equity share, for the financial year ended June 30, 2021, which includes a one-time special dividend of Rs. 90 per equity share. The dividend shall be paid between November 15, 2021 to December 08, 2021, on approval of the Members at the 54th Annual General Meeting.

Kindly take the same on record.

Thanking you.

Yours faithfully,

For Procter & Gamble Health Limited

MILIND
VASANT
THATTE

Digitally signed by
MILIND VASANT
THATTE
Date: 2021.08.26
19:17:18 +05'30'

Milind Thatte
Managing Director

Procter & Gamble Health Limited

CIN: L99999MH1967PLC013726

Registered Office: Godrej One, 8th Floor,

Pirojshanagar, Eastern Express Highway, Vikhroli East,

Mumbai 400 079 | Tel: (91-22) 6866 9000

www.pghealthindia.com

PROCTER & GAMBLE HEALTH LIMITED							
Regd. Office: Godrej One, 8th Floor, Eastern Express Highway, Pirojshanagar, Vikhroli (East), Mumbai : 400 079. CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com							
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30 JUNE 2021							
(₹ in lakhs)							
Sr. No.	Particulars	(1) Three months ended 30th June 2021 Audited [Refer note 6]	(2) Preceding Three months ended 31st March 2021 Unaudited	(3) Corresponding Three months ended 30th June 2020 Audited [Refer note 6]	(4) Year ended 30th June 2021 Audited	(5) Twelve months ended 30th June 2020 Unaudited [Refer note 5]	(6) Eighteen months ended 30th June 2020 Audited
1.	Revenue from Operations	28,539.0	21,915.0	20,115.6	100,873.0	89,119.6	135,586.0
2.	Other Income	242.0	324.0	1,068.3	1,810.0	3,372.7	6,889.0
3.	Total income (1+2)	28,781.0	22,239.0	21,183.9	102,683.0	92,492.3	142,475.0
4.	Expenses						
	a) Cost of materials consumed	7,190.0	7,750.0	5,277.0	28,912.0	25,493.6	41,609.6
	b) Purchases of stock-in-trade	814.0	360.0	213.0	2,116.0	1,863.1	2,837.4
	c) Changes in inventories of finished goods,work-in-progress and stock in trade	946.0	(1,432.0)	(351.5)	454.0	1,617.1	(1,303.0)
	d) Employee benefits expense	4,388.0	3,754.5	3,556.9	15,047.0	11,922.7	18,293.0
	e) Depreciation and amortisation expense	716.0	767.0	804.7	3,004.0	2,061.8	2,945.0
	f) Finance Costs	17.0	20.0	-	80.0	-	-
	g) Other expenses	10,357.0	8,409.5	6,111.1	29,742.0	27,147.8	42,608.0
	Total expenses (4)	24,428.0	19,629.0	15,611.2	79,355.0	70,106.1	106,990.0
5.	Profit before exceptional items and tax (3-4)	4,353.0	2,610.0	5,572.7	23,328.0	22,386.2	35,485.0
6.	Less: Exceptional items	-	-	-	-	-	-
7.	Profit before tax (5-6)	4,353.0	2,610.0	5,572.7	23,328.0	22,386.2	35,485.0
8.	Tax expenses						
	Current Tax	1,322.0	850.0	1,571.4	6,360.0	5,308.0	10,278.0
	Deferred Tax	(377.0)	28.0	(84.7)	(490.0)	949.0	599.0
	Tax for earlier years	19.0	155.0	(800.0)	(222.0)	(800.0)	(800.0)
9.	Net Profit for the period/ year (7-8)	3,389.0	1,577.0	4,886.0	17,680.0	16,929.2	25,408.0
10.	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss						
	i. Re-measurement gains/(losses) on defined benefit plans	551.0	495.0	(309.1)	56.0	(1,137.0)	(1,237.0)
	ii. Income tax effect	(139.0)	(124.0)	77.4	(14.0)	276.0	311.0
	Total Other Comprehensive Income, net of tax	412.0	371.0	(231.7)	42.0	(861.0)	(926.0)
11.	Total Comprehensive Income for the period/year (9+10)	3,801.0	1,948.0	4,654.3	17,722.0	16,068.3	24,482.0
12.	Paid-up equity share capital (Face Value Rs 10/- each)	1,660.0	1,660.0	1,660.0	1,660.0	1,660.0	1,660.0
13.	Other equity excluding Revaluation reserve as per Balance sheet	-	-	-	68,711.0	-	88,974.0
14.	Earnings per equity share (of Rs 10/- each) *(not annualised) (a) Basic and Diluted (in Rs.)	* 20.4	* 9.5	* 29.4	* 106.5	* 102	* 153.1

MILIND
VASANT
THATTE

Digitally signed by
MILIND VASANT THATTE
Date: 2021.08.26 18:38:56
+05'30'

PROCTER & GAMBLE HEALTH LIMITED

Balance Sheet as at 30 June 2021

		(Rs in lakhs)	
		As at June 30, 2021 [Audited]	As at June 30, 2020 [Audited]
Non-current assets			
(a)	Property, plant and equipment	9,337	9,771
(b)	Capital work-in-progress	3,915	2,145
(c)	Investment property	295	330
(d)	Right -of -use assets	747	-
(e)	Intangible assets	12	21
(f)	Financial assets		
	(i) Loans	541	7
	(ii) Other financial assets	818	776
(g)	Deferred tax assets (net)	1,991	1,515
(h)	Other non-current assets	609	664
(i)	Non-current tax assets (Net)	7,637	6,989
Total non-current assets		25,902	22,218
Current assets			
(a)	Inventories	11,837	13,411
(b)	Financial assets		
	(i) Trade receivables	5,943	9,527
	(ii) Cash and cash equivalents	46,405	63,569
	(iii) Bank balances other than (ii) above	486	340
	(iv) Loans	145	9
	(v) Other financial assets	598	401
(c)	Other current assets	7,300	8,099
Total current assets		72,714	95,356
TOTAL ASSETS		98,616	117,574
<u>EQUITY AND LIABILITIES</u>			
Equity			
(a)	Equity share capital	1,660	1,660
(b)	Other equity	68,711	88,974
Total Equity		70,371	90,634
Non-Current Liabilities			
(a)	Financial liabilities		
	(i) Other financial liabilities	286	-
(c)	Provisions	4,005	4,085
(b)	Other non-current liabilities	57	121
Total non-current liabilities		4,348	4,206
Current liabilities			
Financial liabilities			
(a)	Trade payables		
	(i) total outstanding dues of micro enterprises and small enterprises	600	699
	(ii) total outstanding dues of creditors other than micro enterprises and	12,276	11,697
(b)	Other financial liabilities	9,586	8,563
(c)	Other current liabilities	824	888
(d)	Provisions	186	436
(e)	Current tax liabilities (net)	425	451
Total current liabilities		23,897	22,734
TOTAL EQUITY & LIABILITIES		98,616	117,574

MILIND
VASANT
THATTE

Digitally signed
by MILIND
VASANT THATTE
Date: 2021.08.26
18:39:13 +05'30'

Procter & Gamble Health Limited

Statement of Cash Flows for the year ended 30th June 2021

	Year ended June 30, 2021 ₹ in lakhs	18 months ended June 30, 2020 ₹ in lakhs
A. Cash Flows from Operating Activities		
Profit before tax	23 328	35 485
Adjustments for:		
Net unrealised foreign exchange loss	305	66
Rent equalisation reserve	----	54
Allowance for doubtful receivables	108	(107)
Inventory written off	48	----
GST input credit written off	354	----
Depreciation of property, plant and equipment	3 004	2 945
Income from letting of office premises	(209)	(325)
Provision for employee benefits	537	1 472
Loss on sale of property, plant and equipment	42	325
Share-based payment to employees	193	194
Provisions no longer required written back	----	(242)
Finance Cost	80	----
Interest income	(1 506)	(5 598)
Operating profit before working capital changes	26 284	34 269
Working capital adjustments:		
Decrease/ (Increase) in inventories	1 526	(2 075)
Decrease/ (Increase) in trade receivables	3 470	(2 920)
(Increase)/ Decrease in financial and other Assets	(684)	1 405
Increase in trade payables	181	3 547
Increase/ (Decrease) in other liabilities and provisions	762	(530)
Cash generated from operations	31 538	33 696
Income taxes paid (net)	(6 812)	(10 159)
Net cash generated from operating activities (A)	24 726	23 537
B. Cash Flows from Investing Activities		
Purchase and construction of property, plant and equipment	(5 258)	(2 327)
Proceeds from sale of asset	121	30
Income from letting of office premises	209	325
Interest received	1 708	6 056
Redemption of bank deposits	----	12 381
Security deposit placed against commitments	(7)	----
Net cash (used in)/ generated from investing activities (B)	(3 227)	16 464
C. Cash flow from financing activities		
Dividend paid	(38 178)	(73 325)
Dividend tax paid	----	(15 016)
Payment of lease liability	(485)	----
Net cash flow used in financing activities (C)	(38 663)	(88 341)
Net (decrease)/ increase in cash and cash equivalents (A+B+C)	(17 164)	(48 340)
Cash and cash equivalents at the beginning of the year/ period	63 569	1 11 909
Cash and cash equivalents at the end of the year/ period	46 405	63 569
Components of Cash and Cash equivalents:		
Cash in Hand	----	----
Cheque in hand	457	----
Balance with Banks		
In Current accounts	4 638	4 229
In Term deposits (less than 3 months maturity)	41 310	59 340
	46 405	63 569

Note:

The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS 7) - Statement of Cash Flows.

MILIND
VASANT
THATTE

Digitally signed by
MILIND VASANT
THATTE
Date: 2021.08.26
18:39:30 +05'30'

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: Godrej One, 8th Floor, Eastern Express Highway, Pirojshanagar, Vikhroli (East), Mumbai : 400 079.

CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

Notes:

1. The above audited financial Results for the quarter and year ended June 30, 2021 have been reviewed and recommended by the Audit Committee and approved by the Board at its meeting held on August 26, 2021. The Statutory Auditors have issued audit report with unmodified opinion on the financials Statement for the year ended June 30, 2021.
2. Results for all above period have been prepared in accordance with Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended.
3. Effective July 1, 2020, the Company has adopted Ind AS 116, Leases and applied the standard to its Leases using the modified retrospective approach. Accordingly, the Company has not restated comparative information. This has resulted in recognising a lease liability measured at present value of the remaining lease payments and a corresponding Right-of-Use (ROU) asset as if the lease has been commenced w.e.f. 1st July 2020. The Company discounted remaining lease payments using the lessee's incremental borrowing rate as at 1st July 2020. The Company has also elected not to apply the requirements of Ind AS 116 to short term leases and leases for which underlying asset is of low value. In the results for the current period, the nature of expenses in respect of Operating lease has changed from lease rent in previous periods to depreciation cost for the right-of-use asset and finance cost for interest accrued on lease liability. The Company has therefore recognised a lease liability and a corresponding ROU asset as at 1st July 2020. The net impact of this adoption is not material on the results for the period and earning per share.
4. The Company operates under only one segment i.e. Pharmaceuticals. Accordingly, no separate segment information has been provided.
5. Figures for the twelve months ended June 30, 2020 are the balancing figures between the reported audited figures of the Eighteen months ended June 30, 2020 and six months ended June 30, 2019, which are presented in the unaudited financial result for the purpose of comparison with comparable period of current period year to date figures.
6. The figures for the last quarter of the current year and of the previous period are the balancing figures between audited figures in respect of the full financial year/period and year to date reviewed figures upto the end of the third/fifth quarter respectively.
7. The Board of Directors at its meeting held on August 26, 2021 have recommended a payment of final dividend of ₹ 130 per equity share of face value of ₹10 each for the year ended June 30, 2021 resulting in a dividend payout of ₹ 21 579 lakhs.
8. Previous period figures have been regrouped / reclassified wherever necessary.

For Procter & Gamble Health Limited

MILIND
VASANT
THATTE

Digitally signed
by MILIND
VASANT THATTE
Date: 2021.08.26
18:38:28 +05'30'

Milind Thatte
Managing Director
DIN No.08092990

Place : Mumbai

Date : 26 August 2021

Please visit us at our website www.pghealthindia.com

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Procter & Gamble Health Limited

Report on the Audit of the Financial Results

Opinion

We have audited the accompanying annual financial results of **Procter & Gamble Health Limited** ("the Company") for the year ended June 30, 2021 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

- (i) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards, and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended June 30, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Statement under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibility for the Financial Results

This Statement has been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair

view and is free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

HARIBHAKTI & CO. LLP

Chartered Accountants

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended June 30, 2021, being the balancing figure between audited figures in respect of full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W / W100048

HEMANTKUMAR
JAYANTIPRASAD
BHATT

Digitally signed by
HEMANTKUMAR
JAYANTIPRASAD BHATT
Date: 2021.08.26
19:11:20 +05'30'

Hemant J. Bhatt

Partner

Membership No.036834

UDIN: 21036834AAAABG6611

Place: Mumbai

Date: August 26, 2021



Procter & Gamble Health Limited Announces Fourth Quarter and Fiscal Year Results

- Sales of ₹ 990.8 crore and PAT of ₹ 176.8 crore for year ended June 30, 2021
 - Sales for the quarter up by +40%

Mumbai, Aug 26, 2021: Procter & Gamble Health Limited announced today its financial results for the quarter and fiscal year ended 30th June, 2021. The company has recorded a strong performance with sales of ₹281 Crores in the Quarter ending June 30th, up by +40% Vs year ago in a tough environment backed by a sustained demand for our trusted quality vitamins, minerals and supplements. The company recorded sales of ₹ 990.8 crore for the twelve-month fiscal year ending 30th June 2021. Results for the fiscal are not comparable Vs ₹1,329 Crore sales for the eighteen months period last year ending 30th June 2020. Profit After Tax (PAT) for the year ended 30th June 2021 is ₹ 176.8 crores against ₹ 254.08 crores in the previous 18 months fiscal year ended 30th June 2020.

Milind Thatte, Managing Director, Procter & Gamble Health Limited said, *“Given the uncertainty still presented by the pandemic, we continue to work towards protecting the health and safety of our employees and partners, ensuring uninterrupted supplies of our vitamins, minerals, supplements and medicinal products for our patients and consumers, and on supporting communities and relief efforts. As part of the ‘P&G Suraksha India’ Covid-19 relief program, we contributed to the donation of 10 lakh vaccine doses for 5 lakh citizens in partnership with state governments and local authorities. We continue to invest in strengthening public health in India through our flagship CSR program ‘SEHAT’ (meaning Health). Under SEHAT, we recently announced a 3-year collaboration with Tata Trusts for ‘YES To POSHAN’, a new initiative which aims to advance the nutritional status of women and children at grassroots.”*

He further added, *“We continued our journey to strengthen our presence in consumer health focused on offering superior brands, driving increased reach, and improving awareness. The year saw increasing awareness on preventive healthcare and the benefits of supplementation amongst consumers and healthcare professionals (HCPs) reflecting in a strong performance with sales of ₹ 281.1 Crores in the last quarter and ₹ 990.8 Crores during the year ended 30th June 2021 amidst challenging circumstances. While the pandemic continued to impact our day-to-day field operations and manufacturing, we are very proud of our team for pivoting with agility and customer-focus, embracing new technology and ways of working.”*

The Board of Directors have recommended a final dividend of ₹130 per Equity Share, which includes a one-time special dividend of ₹90 per Equity Share, for the Financial Year ended June 30, 2021, subject to the approval of shareholders of the company at the ensuing 54th Annual General Meeting.

About Procter & Gamble Health Limited: Procter & Gamble Health Limited is one of India's largest VMS Companies manufacturing and marketing over-the-counter vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit www.pghealthindia.com for the latest news and information about Procter & Gamble Health Limited and its brands.

About Procter & Gamble:

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide.

CONTACTS

Media Contacts - Procter & Gamble Health Limited:

- Ruchita Mehra | mehra.r@pg.com
- Paromita Kundu | kundu.p.1@pg.com

Investor Relations Contact:

- Flavia Machado | machado.f.1@pg.com

Registered Office :

Procter & Gamble Health Limited
CIN: L99999MH1967PLC013726
Godrej One, 8th Floor, Pirojshanagar,
Eastern Express Highway, Vikhroli East,
Mumbai 400 079 | Tel: (91-22) 6866 9000

Site Address:

Procter & Gamble Health Limited
CIN: L99999MH1967PLC013726
Usgaon, Ponda Taluka,
Goa 403 407 | Tel: (91-832) 2347105
www.pghealthindia.com



August 26, 2021

To,
The Corporate Relations Department
The BSE Limited
of Corporate Services
Towers,
Dalal Street, Mumbai 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited Department
Exchange Plaza, Plot No. C/1, G Block, Phiroze Jeejeebhoy
Bandra Kurla Complex, Bandra (East),
Mumbai 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub: Declaration with respect to Audit Report with unmodified opinion to the Audited Financial Results for the Financial Year ended June 30, 2021

We hereby declare that Audited Financial Results for the Financial Year ended June 30, 2021 which have been approved by the Board of Directors of the Company at meeting held today, i.e., August 26, 2021, the Statutory Auditors, Haribhakti & Co. LLP have not expressed any modified opinion(s) in their Audit Report.

The above declaration is made pursuant to Regulation 33 (3) (d) of the Securities Exchange and Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Kindly take the same on record.

Thanking you.

Yours faithfully,
For Procter & Gamble Health Limited

MILIND VASANT
THATTE

Digitally signed by
MILIND VASANT THATTE
Date: 2021.08.26
19:17:58 +05'30'

Milind Thatte
Managing Director

Procter & Gamble Health Limited

CIN: L99999MH1967PLC013726

Registered Office: Godrej One, 8th Floor,
Pirojshanagar, Eastern Express Highway, Vikhroli East,
Mumbai 400 079 | Tel: (91-22) 6866 9000
www.pghealthindia.com